Pipeline
Focused on the Retina
Our pipeline is focused on tackling the leading causes of blindness, beginning with wet AMD*.
| Program | Therapeutic Focus | Preclinical | Early/Mid Clinical Stage (Phase 1 – Phase 2) | Pivotal Clinical Trial Stage (Phase 3) | FDA Approval | ||
|---|---|---|---|---|---|---|---|
|
Program
|
Therapeutic Focus
Wet AMD*
|
Preclinical
|
Early/Mid Clinical Stage (Phase 1 – Phase 2)
|
Pivotal Clinical Trial Stage (Phase 3)
|
|
||
|
Program
|
Therapeutic Focus
Diabetic Retinopathy
|
Preclinical
|
Early/Mid Clinical Stage (Phase 1 – Phase 2)
|
|
|
||
|
Program
|
Therapeutic Focus
Glaucoma and ocular hypertension
|
Preclinical
|
Early/Mid Clinical Stage (Phase 1 – Phase 2)
|
|
|
* Age-related Macular Degeneration (AMD)
Caution: All investigational product candidates are currently undergoing clinical evaluation. This chart is not intended to convey any conclusion of safety or efficacy, and there is no guarantee that any product candidate will successfully complete development or gain FDA approval.
Our Technology
ELUTYXTM
Our ELUTYX technology is a versatile platform employed to create sustained-release therapies that may expand treatment options across multiple ocular conditions.
CLINICAL TRIALS
